Galecto Inc
NASDAQ:GLTO
Intrinsic Value
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. [ Read More ]
The intrinsic value of one GLTO stock under the Base Case scenario is 1.22 USD. Compared to the current market price of 0.78 USD, Galecto Inc is Undervalued by 36%.
Valuation Backtest
Galecto Inc
Run backtest to discover the historical profit from buying and selling GLTO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Galecto Inc
Current Assets | 36.8m |
Cash & Short-Term Investments | 33.2m |
Receivables | 2.8m |
Other Current Assets | 859k |
Non-Current Assets | 1.5m |
PP&E | 325k |
Other Non-Current Assets | 1.1m |
Current Liabilities | 5.8m |
Accounts Payable | 1.7m |
Accrued Liabilities | 2.9m |
Other Current Liabilities | 1.2m |
Non-Current Liabilities | 66k |
Other Non-Current Liabilities | 66k |
Earnings Waterfall
Galecto Inc
Revenue
|
0
USD
|
Operating Expenses
|
-36.5m
USD
|
Operating Income
|
-36.5m
USD
|
Other Expenses
|
-1.9m
USD
|
Net Income
|
-38.3m
USD
|
Free Cash Flow Analysis
Galecto Inc
What is Free Cash Flow?
GLTO Profitability Score
Profitability Due Diligence
Galecto Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Galecto Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
GLTO Solvency Score
Solvency Due Diligence
Galecto Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Galecto Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLTO Price Targets Summary
Galecto Inc
Ownership
GLTO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GLTO Price
Galecto Inc
Average Annual Return | -51.03% |
Standard Deviation of Annual Returns | 31.51% |
Max Drawdown | -97% |
Market Capitalization | 21.1m USD |
Shares Outstanding | 27 104 777 |
Percentage of Shares Shorted | 0.27% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. The firm is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.
Contact
IPO
Employees
Officers
The intrinsic value of one GLTO stock under the Base Case scenario is 1.22 USD.
Compared to the current market price of 0.78 USD, Galecto Inc is Undervalued by 36%.